SCHEMBL504015

SCHEMBL504015

Cc1c(F)cccc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.61
ESR1 P03372 1/20 0.53
ESR2 Q92731 1/20 0.53
TSHR P16473 1/20 0.52
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 3/20 0.50
HPGD P15428 2/20 0.50
CES2 O00748 2/20 0.48
CES1 P23141 2/20 0.48
BCHE P06276 1/20 0.48
ALOX15 P16050 2/20 0.48
NOTUM Q6P988 1/20 0.46
MYC P01106 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
NAPRT Q6XQN6 2/20 0.44
MEN1 O00255 1/20 0.44
AKR1B10 O60218 1/20 0.44
TRPA1 O75762 1/20 0.44
ABCB11 O95342 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29570483 1.00 ALB (0.61) ALBESR1ESR2TSHRALDH1A1
SCHEMBL27703149 0.84 TSHR (0.61) TSHRALDH1A1KDM4EHSD17B10HPGD
Benzene SCHEMBL27265959 0.84 TSHR (0.61) TSHRALDH1A1KDM4EHSD17B10HPGD
SCHEMBL756585 0.84 TSHR (0.61) TSHRALDH1A1KDM4EHSD17B10HPGD
SCHEMBL25198802 0.83 ALB (0.45) ALBESR1ESR2TSHRALDH1A1
SCHEMBL11476967 0.83 ESR1 (0.53) ALBESR1ESR2ALDH1A1HPGD
SCHEMBL4451884 0.83 ESR1 (0.53) ALBESR1ESR2ALDH1A1KDM4E
SCHEMBL17040388 0.83 ESR1 (0.53) ALBESR1ESR2ALDH1A1HSD17B10
SCHEMBL27479457 0.81 TSHR (0.59) TSHRALDH1A1KDM4EHSD17B10HPGD
SCHEMBL10768142 0.81 TSHR (0.59) TSHRALDH1A1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024342-B Synthesis method of phenanthridine OLED material 上海海皋科技有限公司 2024-11-08 CN claimed
CN-118206444-A Synthesis method of 6-bromo-3-fluoro-2-methylbenzoic acid 上海毕得医药科技股份有限公司 2024-06-18 CN claimed
CN-117024342-A Synthesis method of phenanthridine OLED material 上海海皋科技有限公司 2023-11-10 CN claimed
CN-116836081-A Ether epoxy toughening agent and preparation method and application thereof 中国林业科学研究院林产化学工业研究所 2023-10-03 CN claimed
CN-116375734-A Ballon Sha Weizhi isomer and preparation method thereof 思科(深圳)药物研发有限公司 2023-07-04 CN claimed
CN-109212056-B Gas chromatography-mass spectrometry combined method for determining three trace monohalogenated methylbenzoic acids in water source water 丁立平 2021-05-07 CN claimed
CN-110357850-A A kind of preparation method of sulfur heterocyclic compound 广东东阳光药业有限公司 2019-10-22 CN claimed
CN-110204433-A The synthetic method of the fluoro- 2- methyl benzoic acid of 3,4- of one kind bis- 湖南师范大学 2019-09-06 CN claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS ALB 2723/4885ESR1 4599/4885ESR2 4600/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 ALB 1055/4885ESR1 1511/4885ESR2 1600/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 ALB 137/4885ESR1 4582/4885ESR2 4815/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS ALB 2723/4885ESR1 4599/4885ESR2 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.